Search clinical trials for: PEM

Total 4721 results

Yonsei University

Not yet recruiting

Pazopanib With or Without Pembrolizumab for Metastatic Soft Tissue Sarcoma

Soft Tissue Sarcoma
AbelZeta, Inc.
Nektar Therapeutics

Recruiting

C-TIL051 in Non-Small Cell Lung Cancer

Metastatic Non Small Cell Lung Cancer

United States
M.D. Anderson Cancer Center
Gilead Sciences

Recruiting

A Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC)

Breast Cancer

United States
National Cancer Institute (NCI)

Recruiting

Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Metastatic Triple-Negative Breast Carcinoma | Unresectable Triple-Negative Breast Carcinoma

United States
Diwakar Davar
Gateway for Cancer Research

Not yet recruiting

Responder-derived FMT (R-FMT) and Pembrolizumab in Relapsed/Refractory PD-L1 Positive NSCLC

Non Small Cell Lung Cancer

United States
Dizal Pharmaceuticals

Recruiting

A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
University of Florida
Merck Sharp & Dohme LLC

Recruiting

A Study of Oral IRAK-4 Inhibitor CA-4948 in Combination With Pembrolizumab Following Stereotactic Radiosurgery in Patients With Melanoma Brain Metastases

Melanoma Metastatic in the Brain

United States
Laboratorio Elea Phoenix S.A.
Syneos Health

Recruiting

Double-blind Study to Evaluate the PK, Efficacy, Safety and Immunogenicity of MB12 Versus Keytruda® in Stage IV NSCLC

Non Small Cell Lung Cancer Metastatic

Georgia, Chile, Argentina
M.D. Anderson Cancer Center
Tvardi Therapeutics, Inc

Not yet recruiting

Phase I/II Open Label Study Evaluating the Safety and Efficacy of Combining STAT3 Inhibition (TTI-101) With Anti-PD-1 Therapy (Pembrolizumab) in Patients With Recurrent or Metastatic (RM) Head and Neck Squamous Cell Carcinoma (HNSCC)

Head and Neck Squamous Cell Carcinoma
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer

Advanced Lung Cancer

China
Sidney Kimmel Comprehensive Cancer Center at Johns...
Merck Sharp & Dohme LLC; Astellas Pharma Inc; Seagen Inc.

Not yet recruiting

Renal Retention in High Grade Upper Tract Urothelial Cancer

Bladder Cancer | Urothelial Carcinoma Bladder | High Grade Urothelial Carcinoma

United States
Asher Biotherapeutics, Inc.
Merck Sharp & Dohme LLC

Recruiting

A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors

Melanoma | Renal Cell Carcinoma | Solid Tumor | Non Small Cell Lung Cancer | Squamous Cell Carcinoma of Head and Neck

United States
Tianjin Medical University Cancer Institute and...

Recruiting

Pemigatinib in the Advanced Gastrointestinal Cancer With FGFR 1-3 Alterations

Gastrointestinal Cancer

China
Roswell Park Cancer Institute
United States Department of Defense

Recruiting

Propranolol in Combination With Pembrolizumab and Standard Chemotherapy for the Treatment of Unresectable Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Adenocarcinoma

Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Metastatic Gastroesophageal Junction Adenocarcinoma | Unresectable Gastroesophageal Junction Adenocarcinoma | Locally Advanced Gastroesophageal Junction... and other conditions

United States
Taizhou Hanzhong biomedical co. LTD

Not yet recruiting

A Study of HX008 Plus Transcatheter Arterial Chemoembolization (TACE) in the First-Line Treatment of Subjects With Stage IV (M1c) Melanoma That is Metastatic to the Liver

Melanoma Neuroendocrine Tumors Neuroectodermal Tumors Neoplasms Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms Neoplasms

China
Qianfoshan Hospital

Recruiting

First-Line Treatment for Advanced Non-squamous Non-Small-Cell Lung Cancer With Negative Driver Gene: a Single-center, Single-Arm Trial (SPBPDC)

Advanced Non-squamous Non-Small-Cell Lung Cancer

China
Cynata Therapeutics Limited

Recruiting

A Study of CYP-001 in Combination With Corticosteroids in Adults With High-risk aGvHD

Graft Versus Host Disease, Acute

United States, Australia, Turkey
University of Kansas Medical Center

Recruiting

Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC (NeoTRACT)

Breast Cancer | Triple Negative Breast Cancer

United States
Klus Pharma Inc.

Recruiting

SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors

Solid Tumor

China
Akeso

Recruiting

Study of AK119 and AK112 With or Without Chemotherapy for NSCLC Patients

NSCLC

China
Sanguine Biosciences

Recruiting

Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives

Heart Diseases | Stroke | Lymphoma | Multiple Sclerosis | Kidney Diseases | Diabetes | Leukemia | Age-Related Macular Degeneration | Cancer | Arthritis | Schizophrenia | Thyroid Diseases | Parkinson Disease | Hepatitis | Vasculitis | Psoriasis | Asthma | Amyloidosis | Fibromyalgia | Graves Disease | Alzheimer Disease | Celiac Disease | Cirr... and other conditions

United States
Imperial College London
Cancer Research UK

Recruiting

A Feasibility Window Study of Pembrolizumab Prior to Second Evacuation for Post-molar Gestational Trophoblastic Neoplasia

Gestational Trophoblastic Neoplasia | Gestational Trophoblastic Disease | Gestational Trophoblastic Tumor, Recurrent

United Kingdom
BeiGene

Recruiting

A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer | Metastatic Non-small Cell Lung Cancer

United States, China, Australia, Spain, Malaysia, Italy, Canada, Thailand, Georgia, Brazil, Korea, Republic of, Singapore, Moldova, Republic of, Romania
M.D. Anderson Cancer Center

Recruiting

A Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination With Mitotane in Patients With Advanced Adrenocortical Carcinoma

Adrenocortical Carcinoma

United States
Gilead Sciences
Arcus Biosciences, Inc.

Recruiting

Study of Novel Treatment Combinations in Patients With Lung Cancer (VELOCITY-Lung)

Lung Cancer | Advanced or Metastatic Non-Small-Cell Lung Cancer | Resectable Non-Small-Cell Lung Cancer

United States, Korea, Republic of, Taiwan, Hong Kong, Israel, United Kingdom
SWOG Cancer Research Network
National Cancer Institute (NCI); Eli Lilly and Company; Merck Sharp & Dohme LLC

Recruiting

Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study

Stage IV Lung Cancer AJCC v8 | Recurrent Lung Non-Small Cell Carcinoma

United States
Gilead Sciences
Alliance Foundation Trials, LLC.; NSABP Foundation Inc

Recruiting

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/NSABP B-63) (ASCENT-05)

Triple Negative Breast Cancer

United States
AstraZeneca
SWOG Clinical Trials Partnerships; Daiichi Sankyo

Recruiting

A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)

Breast Cancer

United States, China, Denmark, United Kingdom, Korea, Republic of, Canada, Germany, Italy, Belgium, Spain, Japan, France, Taiwan, Greece, Brazil, Sweden, Puerto Rico
NRG Oncology
National Cancer Institute (NCI)

Recruiting

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-small Cell Lung Cancer

Stage III Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Locally Advanced Lung Non-Small Cell Carcinoma

United States
Istituto Scientifico Romagnolo per lo Studio e...
Merck Sharp & Dohme LLC

Recruiting

Pembrolizumab and Olaparib Treatment of Extensive Small Cell Lung Cancer (ES-SCLC) (THOR)

SCLC,Extensive Stage

Italy
Australia New Zealand Gynaecological Oncology Group
Merck Sharp & Dohme LLC; Eisai Inc.

Recruiting

EPOCH: Eribulin and Pembrolizumab in Ovarian/Uterine Carcinosarcoma (EPOCH)

Uterine Carcinosarcoma | Ovarian Carcinosarcoma

Canada, Australia, United Kingdom
Salubris Biotherapeutics Inc

Recruiting

Study of JK08 in Patients With Unresectable Locally Advanced or Metastatic Cancer

Melanoma | Clear Cell Renal Cell Carcinoma | Cancer | Hepatocellular Carcinoma | Colorectal Cancer | Pancreatic Adenocarcinoma | Gastric Adenocarcinoma | Metastatic Cancer | Squamous Cell Carcinoma of Head and Neck | Triple Negative Breast Cancer | Advanced Solid Tumor | Epithelial Ovarian Cancer | Non-small Cell... and other conditions

Belgium, Spain
Bayer

Recruiting

A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid Tumors

Advanced Solid Tumors

United States, United Kingdom, Korea, Republic of, Japan, Spain, Belgium, China
University of Illinois at Chicago

Recruiting

A Pilot Phase II Study of Maintenance Cabozantinib Plus Pembrolizumab for Patients With Metastatic Squamous Non-Small Cell Lung Cancer (sqNSCLC) (LUNG-IST-127)

Metastatic Squamous Non-Small Cell Lung Carcinoma

United States
Eli Lilly and Company
Merck Sharp & Dohme LLC; Loxo Oncology, Inc.

Recruiting

A Study of LOXO-435 in Participants With Cancer With a Change in a Gene Called FGFR3

Urinary Bladder Neoplasms | Neoplasm Metastasis | Ureteral Neoplasms

United States, Korea, Republic of, Spain, United Kingdom, Germany, Japan, France, China, Australia, Netherlands, Canada, Israel, Norway, Italy
Beijing Tsinghua Chang Gung Hospital

Recruiting

Neoadjuvant of Tislelizumab Combined With Chemotherapy Followed by Surgery in Unresectable Stage Ⅲ NSCLC

NSCLC, Stage III

China
Ismail Gögenur

Not yet recruiting

Electroporation and Immunotherapy in Metastatic Colorectal Cancer (ELI)

Metastatic Colorectal Cancer
Mirati Therapeutics Inc.

Recruiting

Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation (202200050434)

Metastatic Lung Cancer | Advanced NSCLC

United States, Spain, Greece, Hungary, France, Italy, Poland
Merck Sharp & Dohme LLC
Gilead Sciences

Recruiting

Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)

Carcinoma, Non-Small-Cell Lung

China, Poland, Latvia, United States, Taiwan, Australia, Turkey, Germany, Israel, Korea, Republic of, Estonia, Romania, Chile, Italy, Brazil, Greece, Philippines, Canada, Japan, Malaysia, United Kingdom, Lithuania, Thailand, Peru
Regeneron Pharmaceuticals

Recruiting

A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery

Melanoma

United States, Australia, Spain, United Kingdom, Canada, Brazil, Mexico, Germany, Ireland, South Africa, France, Israel, Georgia, Turkey, Italy, Poland, Chile, Argentina, Belgium, Czechia, Romania, Greece
Aaron Wolfson

Recruiting

Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma

Recurrent Endometrial Carcinoma | Unresectable Endometrial Carcinoma

United States
Peking Union Medical College Hospital
Merck Sharp & Dohme LLC; BeyondSpring Pharmaceuticals Inc.

Recruiting

Pembrolizumab in Combination With Plinabulin and Docetaxel For Metastatic NSCLC After ICIs (KeyPemls-004) (KeyPemls-004)

Non Small Cell Lung Cancer Metastatic

China
Cairo University

Not yet recruiting

Evaluation of Premixed Verses Powder/Liquid Bioceramic MTA in Indirect Pulp Capping.

Indirect Pulp Capping
Hospital Regional de Alta Especialidad del Bajio
Universidad de Guanajuato

Recruiting

Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma

Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Relapsed Hodgkin's Disease, Adult

Mexico
Cairo University

Recruiting

Ozonated Olive Oil in Treatment of Pemphigus Vulgaris and Bullous Pemphigoid

Bullous Pemphigoid | Pemphigus Vulgaris

Egypt
Merck Sharp & Dohme LLC

Recruiting

A Study of MK-6598 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-6598-001)

Advanced or Metastatic Solid Tumors

Canada, Switzerland, United States
Eli Lilly and Company

Recruiting

A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF)

Heart Failure | Heart Failure With Preserved Ejection Fraction

Spain, United States, Japan, United Kingdom, Czechia, Hungary, Israel, Brazil, Argentina, Canada, Poland, Turkey
Icahn School of Medicine at Mount Sinai

Recruiting

Pembrolizumab for Advanced NSCLC and PS 2-3

Non-Small Cell Lung Cancer (NSCLC)

United States
Shanghai Changzheng Hospital

Not yet recruiting

Preoperative Pembrolizumab Plus Bevacizumab Combined With Chemotherapy in Patients With pMMR/MSS Locally Advanced Colorectal Cancer (COBP)

Locally Advanced Colorectal Cancer
Weill Medical College of Cornell University
Merck Sharp & Dohme LLC; Novartis; GI Research Foundation

Recruiting

Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients With Merkel Cell Cancer (iPRRT)

Merkel Cell Carcinoma

United States

Search clinical trials for: PEM

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ghana

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations